Piperazine and 1-azabicyclo[2.2.2]octane are both present in a new drug candidate CRN04894. To expand future studies, we have created two sets of analogs to those fragments, which can be solid starting points for your research projects:
CRN04894 is a strong and subtype-specific first-in-class nonpeptide MC2R that has shown efficacy in a rat model of adrenocorticotropic hormone (ACTH)-stimulated corticosterone secretion. CRN04894 is now being tested in a first-in-disease Phase Ib/IIa trial in people with ACTH-dependent Cushing's syndrome, as well as a Phase II trial in people with congenital adrenal hyperplasia.
Sounds interesting? Drop us a line at info@chem-space.com
